Share this article:

Allergan Inc. said today that a federal judge has set an Oct. 28 hearing for a preliminary injunction against hostile suitors Valeant Pharmaceuticals International Inc. and activist investor Bill Ackman’s Pershing Square Capital Management LP.

Irvine-based Allergan’s injunction request stems from a lawsuit it filed against Valeant and Pershing in August on alleged violations of federal securities laws, including insider trading.

Get the latest OC business and Coronavirus updates

The maker of Botox and other drugs is fighting a hostile takeover bid by Canada-based Valeant and Ackman, who owns just less than 10% of Allergan, a bid valued at about $51.5 billion.

If the court grants Allergan’s motion, Valeant, Pershing Square and Ackman wouldn’t be able to vote their shares at a Dec. 18 special meeting of Allergan stockholders, the drug maker said in a news release.

Valeant, Pershing and Ackman want to remove a majority of Allergan shareholders and replace them with directors willing to open negotiations.

Allergan said in a statement that today’s ruling “allows us to obtain documents and other evidence, including depositions of key witnesses, so we can promptly develop a thorough factual record regarding the serious issues raised by Allergan’s claims.”

Allergan shares closed up 1% today to a market value of $50.3 billion. Valeant’s shares were also up 1% to a market value of $40.9 billion.